The North America Infectious Respiratory Disease Diagnostics Market would witness market growth of -5.8% CAGR during the forecast period (2022-2028).
The demand for diagnostic tests is growing as a result of the rise in lower respiratory infectious disease, which increases the need for early detection. Likewise, the healthcare industry is experiencing an increase in public-private funding for targeted research initiatives. Also, the number of smokers and drinkers, as well as product innovations and development due to technological advancements all over the world is growing continuously and is anticipated to grow further over the forecast period.
In the future, the market's growth rate will be further accelerated by factors such as unhealthy individual lifestyles, rising internet penetration rates, an ageing population base, an increase in pollution levels, product development and commercialization, and rising per capita health care spending. A common condition, respiratory tract infections can be asymptomatic or present as a minor sickness that progresses to cause major problems, hospitalization, or even death.
Respiratory infections are frequently brought on by influenza and other viral diseases such as adenovirus, respiratory syncytial virus, human metapneumovirus, and rhinovirus. To stop and lessen the transmission of the influenza virus, early detection and diagnosis of the viral infection may enable the proper therapy to be started.
Almost 5 million children and nearly 15 million adults in America currently suffer from asthma. Since 1980, the percentage of asthma cases has nearly doubled. Asthma-related deaths affect 5,500 people annually, and over the past 20 years, the rate has risen. Also, due to the rising burden of COVID-19, a strong health care system, and rising rates of whooping cough, influenza, and other respiratory infections, the demand for respiratory disease.
The US market dominated the North America Infectious Respiratory Disease Diagnostics Market by Country in 2021; thereby, achieving a market value of $7.8 billion by 2028. The Canada market is experiencing a CAGR of -3.6% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of -4.5% during (2022 - 2028).
Based on Product Type, the market is segmented into Consumables, Instruments (Imaging Tests, Respiratory Measurement Devices, and Others), Services. Based on Application, the market is segmented into SARS/COVID 19, Influenza, RSV (Respiratory Syncytial Virus), Tuberculosis, Streptococcus Testing, and Others. Based on Sample Type, the market is segmented into Saliva, Anterior Nasal Region, Blood, Nasopharyngeal Swabs (NPS), and Others. Based on Technology, the market is segmented into Molecular Diagnostics, Microbiology, Immunoassay, and Others. Based on End-use, the market is segmented into Diagnostic Laboratories, Hospitals, and Physician Offices & Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Infectious Respiratory Disease Diagnostics Market is Estimated to reach $ 37.2 Billion by 2028, at a CAGR of -5.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, Siemens Healthineers AG (Siemens AG), Thermo Fisher Scientific, Inc., Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Qiagen N.V., Bio-Rad Laboratories, Inc., Danaher Corporation, Quidel Corporation
By Product Type
By Application
By Sample Type
By Technology
By End Use
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
